Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Psilocybin virkningsmekanisme (MOA)

5. november 2026 opdateret af: James Murrough, Icahn School of Medicine at Mount Sinai

Undersøgelse af serotonins rolle i psilocybins virkningsmekanisme hos patienter med svær depressiv lidelse

This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at several timepoints up to 5 weeks post-dosing.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

In this study, the researchers want to probe the role of the 5-HT2A receptor in mediating the subjective effects of psilocybin. While previous studies have shown that blockage of the 5-HT2A receptor reduces the psychedelic experience in humans, an animal study revealed that blockage of the 5- HT2A receptor abolished the psychedelic effects without affecting the antidepressant response. This suggests that the pathway responsible for the antidepressant response is dissociated from the psychedelic experience pathway, which is mediated by 5-HT2A signaling.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Depression and Anxiety Center Icahn School of Medicine at Mount Sinai
  • Telefonnummer: (212) 241-6539
  • E-mail: dac@mssm.edu

Studiesteder

    • New York
      • New York, New York, Forenede Stater, 10025
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research
        • Ledende efterforsker:
          • James Murrough
        • Kontakt:
          • Depression and Anxiety Center
          • Telefonnummer: (212) 241-6539
          • E-mail: dac@mssm.edu

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 21-80 years, any gender
  • Current primary diagnosis of Unipolar Major Depressive Disorder (MDD) without psychotic features using DSM-5 criteria
  • 24-item Hamilton Rating Scale for Depression (HRSD) ≥16
  • Current diagnosis of Major Depressive Episode (MDE)
  • Capable of providing informed consent and complying with study procedures
  • Currently using or agreeing to use a highly effective contraception, if person of childbearing potential (such as condoms, IUD, or oral contraceptive), for duration of the study. Male participants agree to use highly effective contraception with partners of childbearing potential
  • Discontinuation of any serotonergic drug for at least 2 weeks or 5 half-lives (whichever of the two is longer) prior to psilocybin exposure

Exclusion Criteria:

  • Any severity of substance use disorder in the last 6 months (excluding tobacco use disorder) as determined by DSM-V criteria via the SCID
  • Current psychiatric hospitalization or psychiatric hospitalization within the last 6 months
  • Use of psychedelics in the last 12 months
  • Non-medical or illicit use of ketamine in the past 12 months
  • Negative reaction after prior use of psychedelics
  • Past or current psychotic disorder (including psychotic MDD), mania, or bipolar disorder
  • Severe depression as indicated by Clinical Global Impressions (CGI)-Severity score ≥ 5 at baseline
  • Significant suicidal ideation as indicated by C-SSRS > 2 in the past 6 months at time of screening
  • Suicide attempt in the past 2 years, or clinician concern that the patient poses a risk to self or others
  • Acute, severe, or unstable medical illness
  • Weight > 300 lbs., or girth size incompatible with scanner bore
  • Any conditions/qualities that make participation in MRI imaging unsafe*
  • Any physical or intellectual disability adversely affecting ability to complete assessments.
  • Current pregnancy or currently breast feeding.
  • Any clinically significant abnormal lab test result, including clinically significant abnormal baseline liver and/or renal function tests
  • Currently being treated with a contraindicated medication. Contraindicated medications include antipsychotic medications, serotonergic antidepressant medications, and mood stabilizers that may attenuate the effects of psilocybin. Strong CYP3A4 inhibitors and inducers are also contraindicated. UGT1A9 and UGT1A10 inhibitors, monoamine oxidase, and aldehyde or alcohol dehydrogenase inhibitors are prohibited concomitant medications.
  • History of abnormal QT prolongation or QTc interval >450 ms on screening
  • Use of medications known to prolong the QT interval
  • Any congenital prolongation of the QT interval or a family history of long QT syndrome
  • A family history of sudden cardiac or unexplained death
  • A family history in a first-degree relative of psychosis/schizophrenia or related disorders
  • A first-degree family history of bipolar disorder
  • A history of cardiac arrhythmias or who require treatment with an antiarrhythmic medication
  • A history of any cardiovascular disorder/condition known to increase the possibility of QT prolongation, or any other risk factors for prolonged QT interval/torsades de pointes (including symptomatic bradycardia, hypokalemia, hypomagnesemia, hypocalcemia, heart failure, or Brugada Syndrome)
  • Preexisting cardiovascular conditions, including cardiac valvulopathy, pulmonary hypertension, hypertension, tachycardia, and any cardiovascular conditions that may be worsened/exacerbated by elevated blood pressure or heart rate.
  • Baseline vital sign parameters at screening and on day of dosing prior to dose that exceed to the following values for systolic blood pressure (SBP), diastolic (DBP), and heart rate (HR): SBP > 139 mmHg, DBP 89 mmHg, and HR > 90 bpm
  • Hypersensitivity to either psilocybin or pimavanserin
  • Psychiatric or other condition judged to be incompatible with establishment of rapport with therapy team and/or safe exposure to psilocybin
  • Positive urine toxicology at screening
  • Any clinically significant abnormalities on 12-lead electrocardiogram (ECG)
  • Mini-Mental State Examination (MMSE) score < 25
  • Brief Psychiatric Rating Scale (BPRS-6) > 5
  • Potential fall risk

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Psilocybin + Pimavanserin

single dose Psilocybin and single dose Pimavanserin

Psilocybin, 25mg, given once orally.

Pimavanserin, 34mg, given once orally

Andre navne:
  • Nuplazid
Placebo komparator: Psilocybin + Placebo

single dose Psilocybin and single dose Placebo

Psilocybin, 25mg, given once orally.

Matching placebo.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mystical Experience Questionnaire (MEQ-30) Score
Tidsramme: 6 hours post-treatment

Acute subjective effects of psilocybin measured by the Mystical Experience Questionnaire (MEQ-30). Full Scale ranges from 0 to 150, with higher scores indicating more mystical experience.

6 hours post-treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Montgomery-Åsberg Depression Rating Scale (MADRS) Score
Tidsramme: 7 days after dosing

The Montgomery-Åsberg Depression Rating Scale (MADRS) will be used to measure improvement in depressive symptoms 7 days after dosing. This 10-item clinician-rated scale measures the severity of depressive symptoms. Full scale ranges from 0 to 60, with higher scores indicating more depressive symptoms.

7 days after dosing

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: James Murrough, Icahn School of Medicine at Mount Sinai
  • Ledende efterforsker: Rachel Fremont, Icahn School of Medicine at Mount Sinai

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

25. februar 2025

Primær færdiggørelse (Anslået)

1. marts 2029

Studieafslutning (Anslået)

1. april 2029

Datoer for studieregistrering

Først indsendt

9. september 2024

Først indsendt, der opfyldte QC-kriterier

9. september 2024

Først opslået (Faktiske)

19. september 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • STUDY-23-00855

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Because this study is privately funded, the research team is not required to share IPD.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .